

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/123147 A1

(51) International Patent Classification:

C12N 15/62 (2006.01)	C07K 14/47 (2006.01)
A61K 39/00 (2006.01)	C07K 19/00 (2006.01)
A61K 47/54 (2017.01)	C12N 15/12 (2006.01)
A61P 37/06 (2006.01)	C12N 15/85 (2006.01)
C07J 5/00 (2006.01)	C12N 15/87 (2006.01)

(21) International Application Number:

PCT/CA2024/051664

(22) International Filing Date:

13 December 2024 (13.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/609,977	14 December 2023 (14.12.2023)	US
63/609,983	14 December 2023 (14.12.2023)	US

(71) Applicant: **INTEGRATED NANOTHERAPEUTICS INC.** [CA/CA]; Suite 205, 4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA).

(72) Inventors: **TAM, Yuen Yi**; c/o INTEGRATED NANOTHERAPEUTICS INC., 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA). **CHEN, Sam**; c/o INTEGRATED NANOTHERAPEUTICS INC., 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA). **DENROCHE, Heather**; c/o INTEGRATED NANOTHERAPEUTICS INC., 205-4475 Wayburne Drive, Burnaby, British Columbia V5G 4X4 (CA).

(74) Agent: **WILKE, Mark** et al.; Gowling WLG (Canada) LLP, 2300-550 Burrard Street, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: TOLERIZING IMMUNOMODULATORY COMBINATION




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

(57) Abstract: An immunomodulatory combination that includes a first lipid conjugate, a second lipid conjugate, and one or more nucleic acids. The first lipid conjugate includes a corticosteroid covalently linked to a first lipophilic moiety by a first cleavable linkage or through a first cleavable linker. The second lipid conjugate includes an mTOR/mTORC inhibitor covalently linked to a second lipophilic moiety by a second cleavable linkage or through a second cleavable linker. The one or more nucleic acids encode one or more epitopes targeted by autoreactive T cells, wherein the one or more epitopes comprise one or more class II epitopes. The first lipid conjugate, the second lipid conjugate, and the one or more nucleic acids are co-formulated together in a delivery vehicle, or are formulated in two or three separate delivery vehicles. The immunomodulatory combination may be used for treating autoimmune diseases or conditions involving autoreactive T cells, which includes both CD4+ T cells and CD8+ T cells.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
 - with sequence listing part of description (Rule 5.2(a))
 - in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
-